

Supplementary Table 3. Univariate and multivariate analysis by including APRI (follow-up duration: 5 years)

	Univariate				Multivariable			
	No. of patients	HR	95% CI	P-value	χ^2 score	Adjusted HR	95% CI	P-value
Male sex	8,353 (55.0)	1.96	1.31–2.95	0.001	7.09	2.00	1.20–3.33	0.008
Age (years)								
<50	6,319 (41.6)	1				1		
50–60	4,833 (31.8)	5.64	2.83–11.23	<0.001	16.24	5.01	2.29–10.96	<0.001
60–70	2,668 (17.6)	9.19	4.56–18.53	<0.001	12.21	4.69	1.97–11.15	<0.001
≥70	1,367 (9.0)	13.65	6.55–28.43	<0.001	37.49	13.70	5.93–31.66	<0.001
Bilirubin >18 $\mu\text{mol/L}$	2,537 (16.7)	2.00	1.33–3.01	0.001				
Platelet <150 $\times 10^9/\text{L}$	2,654 (17.5)	3.40	2.34–4.95	<0.001	10.58	2.23	1.37–3.61	0.001
HBV DNA >2,000 IU/mL	8,849 (58.3)	2.07	1.36–3.15	0.001	4.58	1.80	1.05–3.09	0.032
APRI >2	1,019 (7.8)	1.75	0.93–3.29	0.084				
HBeAg (+)	2,431 (16.0)	0.86	0.49–1.49	0.586				
DM	6,785 (44.7)	2.18	1.49–3.19	<0.001				

Values are presented as number (%) unless otherwise indicated.

APRI, aspartate aminotransferase to platelet ratio index; HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; DM, diabetes mellitus.